Literature DB >> 21822826

Targeted drug therapies and cancer.

K L Yim1, D Cunningham.   

Abstract

With the progress of research in molecular biology and greater understanding of cell signalling systems emerge an increasing array of potential targets for the therapy of cancer. While traditional chemotherapy aims to elicit tumour cell death, it also produces undesirable side effects on physiologically proliferating cells. By isolating cell surface receptors which link specific intracellular secondary messenger pathways, researchers are increasingly able to define the biological network which drives cellular function. Of importance are routes involved in malignant transformation, proliferation, survival and angiogenesis. Thus targeted therapy is directed to specific differential growth processes particular to malignant tumours. The principle mode of action generally involves the "lock-and-key" mechanism and identifying the "Achilles' heel" for drug action. Various targeted agents have been studied and many have translated into significant clinical benefit. This chapter will describe some examples which illustrate the role of this approach in gastrointestinal cancers.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21822826     DOI: 10.1007/978-3-642-03503-6_10

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  6 in total

1.  Novel lipoidal amine-based nanocarrier formulations for siRNA delivery.

Authors:  Chenguang Zhou; Zhang Yue; L James Lee; Robert J Lee
Journal:  Ther Deliv       Date:  2012-06

2.  Orobol, an Enzyme-Convertible Product of Genistein, exerts Anti-Obesity Effects by Targeting Casein Kinase 1 Epsilon.

Authors:  Hee Yang; Sang-Hyuk Lee; Hae Ji; Jong-Eun Kim; Ra Yoo; Jong Hun Kim; Sujin Suk; Chul Sung Huh; Jung Han Yoon Park; Yong-Seok Heo; Han-Seoung Shin; Byung-Gee Kim; Ki Won Lee
Journal:  Sci Rep       Date:  2019-06-20       Impact factor: 4.379

3.  Emerging glycolysis targeting and drug discovery from chinese medicine in cancer therapy.

Authors:  Zhiyu Wang; Neng Wang; Jianping Chen; Jiangang Shen
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-12       Impact factor: 2.629

4.  Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.

Authors:  Kein-Leong Yim
Journal:  Cancer Manag Res       Date:  2012-07-31       Impact factor: 3.989

5.  Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice.

Authors:  Bence Kapuvári; Rózsa Hegedüs; Ákos Schulcz; Marilena Manea; József Tóvári; Alexandra Gacs; Borbála Vincze; Gábor Mező
Journal:  Invest New Drugs       Date:  2016-05-05       Impact factor: 3.850

6.  Building Graphs To Describe Dynamics, Kinetics, and Energetics in the d-ALa:d-Lac Ligase VanA.

Authors:  Nathalie Duclert-Savatier; Guillaume Bouvier; Michael Nilges; Thérèse E Malliavin
Journal:  J Chem Inf Model       Date:  2016-09-12       Impact factor: 4.956

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.